### **Overview** Hikal Limited is an India-based specialty chemicals and life sciences company operating as a hybrid Contract Development and Manufacturing Organization (CDMO) with vertically integrated capabilities in **Pharmaceuticals**, **Animal Health**, **Crop Protection**, and **Specialty Chemicals**. The company serves a global clientele of innovator pharmaceutical firms, biotech companies, agrochemical majors, and consumer goods manufacturers, with a strategic focus on complex, high-barrier, and regulated markets. With five manufacturing facilities across India and a state-of-the-art Research & Technology (R&T) center in Pune, Hikal positions itself as a preferred innovation partner to global clients seeking compliant, agile, and scalable development and manufacturing solutions. The company has evolved from a contract manufacturer into a strategic partner leveraging complex chemistry expertise, regulatory compliance, and digital transformation. --- ### **Key Business Segments & Strategic Focus (Nov 2025)** #### **1. Pharmaceuticals & CDMO: Core Growth Engine** - **API Business**: Hikal's pharmaceutical division is the largest and fastest-growing segment, generating ₹11,681 crore in revenue and ₹1,374 crore EBIT in FY24–25 (47% YoY EBIT growth). It specializes in low-volume, high-complexity Active Pharmaceutical Ingredients (APIs), with expertise in: - Chiral chemistry - Custom synthesis - Process development - The company is expanding market share in **Key Molecules** and reducing dependence on regulated markets, enhancing resilience against U.S. tariffs and policy volatility. - A pipeline of **8–9 differentiated APIs** is under development, with **2–3 planned commercial launches annually**, including: - SGLT2 inhibitors (Empagliflozin, Dapagliflozin, Canagliflozin) - Oral anticoagulants: **Apixaban** (pre-patent expiry; $8–10M opportunity in 2028) and Rivaroxaban - 69 active **Drug Master Files (DMFs)** and multiple **Certificates of Suitability (CEPs)** filed, ensuring regulatory readiness in U.S., EU, Japan, and Australia. #### **2. Contract Development and Manufacturing (CDMO)** - Strong and diversified CDMO pipeline with increasing engagement in **technical complexity** and **early-stage RFPs**. - Key drivers: - **“China Plus One”** supply chain diversification trend - Global demand for de-risked, compliant outsourcing - Innovation-led partnerships with tier-1 and tier-2 innovators - Two **Key Starting Materials (KSMs)** for new chemical entities (NCEs) are in **Phase III clinical trials**, expected to commercialize in **FY26–27**. - 12–15 new development opportunities underway, with **8–9 molecules in pipeline**, including high-value small molecules and advanced intermediates. #### **3. High-Potency Active Pharmaceutical Ingredients (HPAPI)** - Inaugurated a **state-of-the-art HPAPI laboratory** in Nov 2025 to enter the high-margin **oncology API market**. - Capabilities in **potent peptides**, **anti-cancer drugs**, and **on-patent oncology products**. - Supports both **pharmaceutical and animal health applications**, expanding Hikal’s presence in niche, high-value markets. - Enables handling of **complex chemistries**, **sterile fill-finish readiness**, and **cGMP compliance**. #### **4. Animal Health: Strategic Growth Pillar** - Emerging as a major long-term growth driver. - Validated **eight products** under a long-term agreement with a global innovator; **commercial scale-up pending regulatory approvals** globally. - Diversified portfolio includes: - Analgesics - Anti-parasitics - Anabolic steroids - NSAIDs - **Multipurpose Animal Health Facility** commissioned at **Panoli, Gujarat**, with full validation in progress. - Patents filed for **three animal health APIs**, with additional R&D in lipid chemistry and green synthesis. - Positioned as a **full-cycle innovation partner**, from early development to commercial manufacturing, with 57 dedicated R&T personnel. #### **5. Crop Protection** - FY24–25 revenue: ₹6,917 crore, EBIT: ₹792 crore (11.4% margin) - Q3 FY25 revenue: ₹154 crore, impacted by pricing pressure from Chinese oversupply but showing **early signs of recovery**. - Strategic shift toward **specialty chemicals and CDMO**, with 8 active CDMO projects. - Launched **sub-brands HiZenn (Personal Care)** and **HiFend (Biocides)** to strengthen market identity. - Despite structural headwinds, Hikal is leveraging its **back-integrated supply chain** and process optimization to improve **capacity utilization** and margins. #### **6. Specialty & Personal Care Chemicals** - Diversification into **high-growth personal care ingredients** using sustainable manufacturing. - 2–3 new products expected to **commercialize in H2 FY26**, with volumes to scale in FY27. - 8 projects in development pipeline, supported by strong traction from global innovators. - Leveraging **green chemistry**, **solvent recovery**, and **Effluent Treatability Labs** to align with ESG goals. - Commissioned **kilo lab and HPAPI lab** to support pilot-scale development. --- ### **R&D and Technology Capabilities** - **R&T Center (Pune)** houses: - 15 synthetic labs - 6 process development labs - HPAPI, high-pressure, solid-state, effluent treatability, and simulation labs - 3 kilo labs for scale-up - **Team**: 250+ postgraduates, 26 PhDs - **Investment**: 4–5% of annual revenue in R&D - **Key Technologies**: - Flow chemistry (CSTR, VaporTech) - Continuous manufacturing - Green chemistry and waste-to-value programs - Solid-state chemistry (polymorph screening, particle engineering) - In-house **High-Resolution Mass Spectrometry (HRMS)** for nitrosamine testing --- ### **Manufacturing Footprint** | Location | Focus Area | |-----------------|----------| | **Jigani, Karnataka** | APIs & Intermediates (US FDA approved) | | **Panoli, Gujarat** | APIs, Animal Health, KSMs (FDA, PMDA, EDQM compliant) | | **Mahad & Taloja, Maharashtra** | Crop Protection Chemicals | | **Bangalore** | Acquired from Wintac; supports CDMO and R&D | - **Total reactor capacity**: ~4,100 m³ - **Pharma capacity**: 1,600–2,500 m³ across sites - **GMP and regulatory compliance** across facilities (FDA, EDQM, PMDA, ANVISA, TGA) --- ### **Global Reach & Customers** - **Markets**: Americas, Europe, Japan, China, Latin America, Middle East, Africa, Asia-Pacific - **Offices**: USA, Europe, India, Japan - Serves global innovators, biotech firms, and MNCs with **end-to-end development and supply chain solutions** - 22+ customer audits passed in FY24–25 - US FDA inspections at Panoli and Jigani facilities yielded **No Action Indicated (NAI) with zero 483 observations** --- ### **Strategic Initiatives (2024–2026)** #### **Project Pinnacle** - Enterprise-wide transformation initiative (now in **Phase 2.0**) focused on: - **Supply chain de-risking** - Digital modernization (Industry 4.0) - ESG leadership (EcoVadis bronze rating, first Sustainability Report published) - Customer centricity (Key Account Management system) - Operational excellence (Self-Managed Teams, HIBEX program) - Aims to diversify across end markets, geographies, and product portfolios for sustainable value creation. #### **Supply Chain Resilience** - Reduced Chinese raw material dependency from ~35% to **<30%** through: - **Backward integration** - Development of **alternate suppliers in India and Europe** - **In-house synthesis of Key Starting Materials** (KSMs) - Positioned as a **China+1 preferred alternative** due to cost, compliance, and agility. #### **Digital Transformation** - IoT, predictive analytics, and PLC-based monitoring systems - Zero Liquid Discharge (ZLD) and **Mechanical Vapor Recompression Evaporator (MVRE)** to reduce effluent and energy costs - Automated solvent management systems --- ### **Financial Highlights (Key Indicators)** - **Pharmaceuticals (FY24–25)**: ₹11,681 Cr revenue, ₹1,374 Cr EBIT (11.8% margin) - **Crop Protection (FY24–25)**: ₹6,917 Cr revenue, ₹792 Cr EBIT (11.4% margin) - **Animal Health**: Targeting **₹300–400 crore revenue in 3–4 years** - **Guidance**: 10–15% CAGR across businesses; **pharma expected to grow at 12–15% from FY26** --- ### **Near-Term Challenges** - **US FDA Compliance**: Resolving OAI status and warning letter issues from H1 FY26. Supply resumption underway; H2 recovery expected to offset H1 shortfalls. - **Pricing Pressure**: In crop protection from Chinese dumping. - **Customer Destocking**: Temporary volume headwinds in CDMO, now largely resolved.